• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months -study

October 5, 2021 by David Barret Leave a Comment

October 5, 2021

By Manas Mishra

(Reuters) – The effectiveness of the Pfizer Inc/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, according to data published on Monday that U.S. health agencies considered when deciding on the need for booster shots.

The data, which was published in the Lancet published medical journal, had been previously released in August ahead of peer review.

The analysis showed that the vaccine’s effectiveness in preventing hospitalization and death remained high at 90% for at least six months, even against the highly contagious Delta variant of the coronavirus.

The data suggests that the drop is due to waning efficacy, rather than more contagious variants, researchers said.

Researchers from Pfizer and Kaiser Permanente studied electronic health records of roughly 3.4 million people who were members of Kaiser Permanente Southern California between December 2020 – when the vaccine first became available – and August of 2021.

“Our variant-specific analysis clearly shows that the (Pfizer/BioNTech) vaccine is effective against all current variants of concern, including Delta,” said Luis Jodar, senior vice president and chief medical officer at Pfizer vaccines.

A potential limitation of the study was a lack of data on adherence to masking guidelines and occupations in the study population, which could have affected frequency of testing and likelihood of exposure to the virus.

Vaccine effectiveness against the Delta variant was 93% after the first month, declining to 53% after four months. Against other coronavirus variants, efficacy declined to 67% from 97%.

“To us, that suggests Delta is not an escape variant that is completely evading vaccine protection,” said study leader Sara Tartof with Kaiser Permanente Southern California’s Department of Research & Evaluation.

“If it was, we would probably not have seen high protection after vaccination, because vaccination would not be working in that case. It would start low, and stay low.”

Testing for variants is more likely to fail in vaccinated individuals, which could lead to overestimation of variant-specific effectiveness in the study, the authors cautioned.

The U.S. Food and Drug Administration has authorized the use of a booster dose of the Pfizer/BioNTech vaccine for older adults and some Americans at high-risk of getting infected. Scientists have called for more data on whether boosters should be recommended for all.

(Reporting by Manas Mishra in Bengaluru; Editing by Bill Berkrot)

Source Link Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months -study

David Barret
David Barret

Related posts:

  1. U.S. pegs farm income at eight-year high amid strong corn, soy prices
  2. UK government plans new pet abduction offence after rise in thefts
  3. North and South Korea conduct missile tests as arms race heats up
  4. Russian authorities arrest cybersecurity giant Group-IB’s CEO on treason charges

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • “Every Species On The Planet Self-Medicates In Some Way”: How Wild Animals Use Medicine
  • Deepest Complex Ecosystem Ever Discovered 10 Kilometers Below The Sea, 892-Kilometer “Megaflash” Lightning Sets New World Record, And Much More This Week
  • The Life And Death Of David Vetter, The Boy Who Lived His Whole Life In A Bubble
  • Time’s Arrow Within Glass Appears To Go Both Ways, Raising Huge Questions
  • World’s “Oldest Baby” Born From Embryo Frozen In 1994 In New World Record
  • What Can Spain’s “Tunnel Of Bones” Tell Us About The Fate Of Human Species On The Brink Of Extinction?
  • Rhino Horns Go Radioactive As Anti-Poaching Project Gets Off The Ground
  • Manta Rays Officially Get Third New Species – 15 Years After First Suspected
  • “Space Hurricanes” Are Happening At Earth’s Poles – And They Can Affect GPS Signals
  • There Is A Crucial Reason Why We Will Never See The Big Bang Directly With Our Telescopes
  • How Does An MRI Machine Work?
  • Catch A Glimpse Of One Of The World’s Rarest Sharks In Dreamy New Footage
  • A One-Shot Vaccine For HIV Might Actually Be On The Cards
  • Chikungunya Virus Is Spreading In China: As CDC Considers Travel Advisory, Here’s What To Know
  • First-Of-Its-Kind Vagus Nerve Implant Gets FDA Approval As A Therapy For Rheumatoid Arthritis
  • First Time Crystal Made Of “Exotic” Giant Atoms 1,000 times Larger Than Hydrogen
  • Prehistoric Humans Began Eating Tubers 700,000 Years Before Our Teeth Evolved To Do So
  • The World’s Oldest Wild Bird “Surprised” Everyone With A Hatched Chick At 74
  • “Spectacular” New Species Of 40cm Giant Stick Insect May Be Australia’s New Heaviest Insect
  • What Is “Nobel Disease”, And Why Do So Many Prizewinners Go On To Develop It?
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version